Monitor PMN310 12-month topline data expected Q1 2027 as the primary catalyst. This CCO appointment signals preparation for potential commercialization but does not change the binary risk of the clinical readout.
Price Chart
Executive Summary
ProMIS Neurosciences appointed Ivana Rubino, Ph.D., as Chief Commercial Officer, effective October 5, 2026. Dr. Rubino brings extensive Alzheimer's disease commercial and development experience from Biogen and Roche, including leadership on the LEQEMBI franchise. The appointment strengthens commercial leadership ahead of PMN310's 12-month topline data expected in Q1 2027.
Key Facts
- Ivana Rubino appointed Chief Commercial Officer effective October 5, 2026
- Dr. Rubino previously served as VP and Global Head, Alzheimer's Disease & MS Medical at Biogen
- She led global medical strategy for LEQEMBI and oversaw 52 market approvals
- Inducement grant of 80,000 stock options at $9.37/share, vesting over 36 months
- PMN310 12-month topline data from PRECISE-AD Phase 1b expected Q1 2027
Financial Impact
Inducement grant of 80,000 options at $9.37/share — minimal dilution relative to outstanding shares
Risk Factors
- PMN310 Phase 1b data may not meet endpoints
- Alzheimer's competitive landscape includes LEQEMBI and other anti-amyloid therapies
- Early-stage biotech with no approved products — high binary risk
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3375334 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 3 | $9.12 $9.15 | ▲ +0.33% | ▲ +0.75% | $8.06 (−11.62%) |
Oct 6, 2026 21d ago | Press Release | $9.21 $9.12 | ▼ −0.98% | ▼ −0.74% | $8.06 (−12.49%) |
Sep 1, 2026 8w ago | Press Release | $13.35 $13.98 | ▲ +4.68% | ▲ +4.24% | $8.06 (−39.63%) |
Jul 14, 2026 15w ago | Press Release | $13.66 $14.01 | ▲ +2.53% | ▲ +2.13% | $8.06 (−41.00%) |
May 28, 2026 21w ago | Press Release | $10.87 $10.81 | ▼ −0.55% | ▼ −0.79% | $8.06 (−25.85%) |
May 12, 2026 24w ago | 8-K | $10.49 $10.57 | ▲ +0.76% | ▲ +0.19% | $8.06 (−23.16%) |
Apr 3, 2026 29w ago | EFFECT | $10.96 $10.88 | ▲ +0.73% | ▲ +0.79% | $8.06 (+26.46%) |
Mar 25, 2026 30w ago | S-3 | $15.13 $14.74 | ▲ +2.58% | ▲ +0.90% | $8.06 (+46.73%) |
Mar 18, 2026 31w ago | S-3 | $18.21 $17.60 | ▲ +3.35% | ▲ +1.61% | $8.06 (+55.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers